<DOC>
	<DOC>NCT00922896</DOC>
	<brief_summary>The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.</brief_summary>
	<brief_title>Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age older than 18 Younger than 75 ECOG performance status 0 or 1 Histologically confirmed adenocarcinoma of the pancreas Metastatic pancreatic cancer No prior chemotherapy for metastatic pancreatic cancer A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT) A patient with no measurable disease A patient who received previous palliative chemotherapy for pancreatic cancer A patient with locally advanced pancreatic cancer A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year A patient with previous active or passive immunotherapy A pregnant or lactating patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Gemcitabine</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Erlotinib</keyword>
</DOC>